High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Spanholtz, Jan ^a   Tordoir, Marleen ^a   Eissens, Diana ^a   Preijers, Frank ^a   Van Meer Der, Arnold ^a   Joosten, Irma ^a   Schaap, Nicolaas ^a   De Witte, Theo M ^a   Dolstra, Harry ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD161 ANTIGEN; CD2 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD94 ANTIGEN; CELL SURFACE MARKER; FLT3 LIGAND; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 6; INTERLEUKIN 7; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2D; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ARTICLE; BLOOD STORAGE; CANCER IMMUNOTHERAPY; CD34 SELECTION; CELL CULTURE; CELL DIFFERENTIATION; CELL EXPANSION; CELL KILLING; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXICITY; DEGRANULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MELANOMA; MICROSCOPY; MYELOID LEUKEMIA; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TUMOR CELL LINE; UMBILICAL CORD BLOOD; CELL PROLIFERATION; CELL STRAIN K 562; CYTOLOGY; FETUS BLOOD; IMMUNOLOGY; IMMUNOPHENOTYPING; LEUKEMIA; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; STEM CELL; TIME;

ANTIGENS, CD34; ANTIGENS, CD56; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FETAL BLOOD; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA; MELANOMA; NEOPLASMS; STEM CELLS; TIME FACTORS;

EID: 77950149420     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009221     Document Type: Article

References (34)

1. Robertson MJ, Ritz J (1990) Biology and clinical relevance of human natural killer cells. Blood 76(12): 2421-2438.
2. Vivier E, Nunes JA, Vely F (2004) Natural killer cell signaling pathways. Science 306(5701): 1517-1519.
3. Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7(5): 329-339.
4. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562): 2097-2100.
5. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, et al. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8): 3051-3057.
6. Passweg JR, Stern M, Koehl U, Uharek L, Tichelli A (2005) Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant 35(7): 637-643.
7. Klingemann HG, Martinson J (2004) Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 6(1): 15-22.
8. Passweg JR, Koehl U, Uharek L, Meyer-Monard S, Tichelli A (2006) Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 19(4): 811-824.
9. McKenna DH, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, et al. (2007) Good manufacturing practices production of natural killer cells for immuno-therapy: a six-year single-institution experience. Transfusion 47(3): 520-528.
10. Koehl U, Esser R, Zimmermann S, Tonn T, Kotchetkov R, et al. (2005) Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr 217(6): 345-350.
11. Iyengar R, Handgretinger R, Babarin-Dorner A, Leimig T, Otto M, et al. (2003) Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 5(6): 479-484.
12. Meyer-Monard S, Passweg J, Siegler U, Kalberer C, Koehl U, et al. (2009) Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation. Transfusion 49(2): 362-371.
13. Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, et al. (2001) A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol 62(10): 1092-1098.
14. Siegler U, Meyer-Monard S, Jorger S, Stern M, Tichelli A, et al. (2008) Expansion of Donor NK Cells for Adoptive Immunotherapy in Haploidentical Stem Cell Transplantation: A Phase I-II Study. ASH Annual Meeting Abstracts 112(11): 3893-.
15. Miller JS, Verfaillie C, McGlave P (1992) The generation of human natural killer cells from CD34+/DR - primitive progenitors in long-term bone marrow culture. Blood 80(9): 2182-2187.
16. Kao IT, Yao CL, Kong ZL, Wu ML, Chuang TL, et al. (2007) Generation of natural killer cells from serum-free, expanded human umbilical cord blood CD34+ cells. Stem Cells Dev 16(6): 1043-1051.
17. Carayol G, Robin C, Bourhis JH, Bennaceur-Griscelli A, Chouaib S, et al. (1998) NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur J Immunol 28(6): 1991-2002.
18. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, et al. (2006) Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 203(4): 1033-1043.
19. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, et al. (2003) Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 101(9): 3730-3740.
20. Mrozek E, Anderson P, Caligiuri MA (1996) Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 87(7): 2632-2640.
21. Lotzova E, Savary CA, Champlin RE (1993) Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors. J Immunol 150(12): 5263-5269.
22. Yu Y, Hagihara M, Ando K, Gansuvd B, Matsuzawa H, et al. (2001) Enhancement of human cord blood CD34+ cell-derived NK cell cytotoxicity by dendritic cells. J Immunol 166(3): 1590-1600.
23. Vitale C, Cottalasso F, Montaldo E, Moretta L, Mingari MC (2008) Methylprednisolone induces preferential and rapid differentiation of CD34+ cord blood precursors toward NK cells. Int Immunol 20(4): 565-575.
24. Perez SA, Sotiropoulou PA, Gkika DG, Mahaira LG, Niarchos DK, et al. (2003) A novel myeloid-like NK cell progenitor in human umbilical cord blood. Blood 101(9): 3444-3450.
25. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, et al. (2009) Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 113(24): 6094-6101.
26. Miller JS, Alley KA, McGlave P (1994) Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. Blood 83(9): 2594-2601.
27. Freud AG, Caligiuri MA (2006) Human natural killer cell development. Immunol Rev 214: 56-72.
28. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, et al. (2007) A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110(2): 578-586.
29. Arai S, Meagher R, Swearingen M, Myint H, Rich E, et al. (2008) Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10(6): 625-632.
30. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, et al. (2009) NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 119(5): 1251-1263.
31. Pietra G, Manzini C, Vitale M, Balsamo M, Ognio E, et al. (2009) Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int Immunol 21(7): 793-801.
32. Punzel M, Gupta P, Roodell M, Mortari F, Verfaillie CM (1999) Factor(s) secreted by AFT024 fetal liver cells following stimulation with human cytokines are important for human LTC-IC growth. Leukemia 13(7): 1079-1084.
33. Overes IM, de Rijke B, van Horssen-Zoetbrood A, Fredrix H, de Graaf AO, et al. (2008) Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. Br J Haematol 141(6): 799-807.
34. Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294(1-2): 15-22.